When Should we Switch from On‐Demand to Prophylaxis Regimen?

[1]  M. Morfini,et al.  Efficacy and safety of secondary prophylactic vs. on‐demand sucrose‐formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13‐month crossover study , 2010, Journal of thrombosis and haemostasis : JTH.

[2]  L. Valentino,et al.  Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  S. Jönsson,et al.  Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years , 2009, European Journal of Clinical Pharmacology.

[4]  P. Petrini,et al.  Haemophilia care in adolescents – compliance and lifestyle issues , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  L. Valentino,et al.  Optimizing outcomes for patients with severe haemophilia A , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  C. Hermans,et al.  Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[8]  C. Hay.  Prophylaxis in adults with haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  E. Santagostino,et al.  International workshop on immune tolerance induction: consensus recommendations 1 , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  M. Franchini,et al.  Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs , 2006, Thrombosis and Haemostasis.

[11]  S. Donadel-Claeyssens.  Current co‐ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management) , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  K. Fischer,et al.  Can long‐term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands , 2005, British journal of haematology.

[13]  F. Rosendaal,et al.  Chronic venous abnormalities in symptomatic and asymptomatic protein C deficiency , 2005, Journal of thrombosis and haemostasis : JTH.

[14]  R. Ljung,et al.  Changing pattern of care of boys with haemophilia in western European centres , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  M. Quintana,et al.  Prophylactic treatment effects on inhibitor risk: experience in one centre , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  L. Valentino.  Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  J. Astermark.  When to start and when to stop primary prophylaxis in patients with severe haemophilia , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  J. Bijlsma,et al.  Immature articular cartilage is more susceptible to blood-induced damage than mature articular cartilage: an in vivo animal study. , 2003, Arthritis and rheumatism.

[19]  D. Grobbee,et al.  The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. , 2002, Blood.

[20]  D. Grobbee,et al.  Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  J. Aznar,et al.  The orthopaedic status of severe haemophiliacs in Spain , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  J. Astermark,et al.  Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized , 1999, British journal of haematology.

[23]  C. Sabin,et al.  Assessing the effectiveness and cost‐effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease , 1998, Journal of internal medicine.

[24]  E. Berntorp.  The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. , 1996, Bailliere's clinical haematology.

[25]  J. Lusher.  Considerations for current and future management of haemophilia and its complications , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  P. Mannucci,et al.  Modern treatment of haemophilia. , 1995, Bulletin of the World Health Organization.

[27]  A. Skolnick.  Hemophilia Foundation recommends prophylactic use of clotting factors. , 1994, JAMA.

[28]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[29]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.